The management of hidradenitis suppurativa (HS) is evolving, but many patients still face significant hurdles in achieving optimal outcomes with current therapies. In this episode, "JAK Inhibition and the Future of HS Treatment," expert dermatologists, Hadar Lev-Tov, MD, and Jennifer L. Hsiao, MD discuss:
Increasing Awareness: Debunking common myths and misconceptions about HS.
Building Trust: Strategies for overcoming diagnostic delays and insufficient management.
Comprehensive Care: Adopting a holistic approach, including addressing common comorbidities.
The Road Ahead: Exploring the future of the HS treatment landscape, including JAK inhibition.
31 Oct 2025
Moving into the Non-Steroidal Topical Therapy Age
This is the final installment of our 4-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." In this episode, "Moving into the Non-Steroidal Topical Therapy Age," we dive into the current and emerging landscape of targeted topical therapies for AD patients. Our experts review the latest clinical data, discuss how they are practically integrating these agents into their practice, and analyze the resulting impact on patient outcomes and their overall approach to AD management. Listen in as board-certified dermatologists, Mona Shahriari, MD and G. Michael Lewitt, MD discuss:
Overview of targeted topical therapies, including next generation topicals
Efficacy of targeted topicals compared to topical steroids
Safety, limitations, and compatibility with other therapies
How to integrate targeted topicals into clinical practice
Pearls for treating pediatric and adult patients across the indicated age range
This podcast is supported by an educational grant from Arcutis Biotherapeutics, Inc.
2 Oct 2025
Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective
The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, "Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective," expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss:
Importance of JAK/STAT signaling in AD and the role of JAK inhibition in the future of dermatology
Long-term safety of topical therapies for chronic AD
Topline efficacy safety data from the phase 3 TRuE-AD3 clinical trial
Shifting the paradigm of topical AD care across patient populations
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
6 ratings
Spotify
5.0 / 5
2 ratings
Podcast Authority Score: 49 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
71
Social presence
0
YouTube
0
Engagement
68
Contact DermDocs
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of DermDocs?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
